CAROTID PLAQUE COMPOSITION BY MRI DURING LIPID-LOWERING

降脂期间颈动脉斑块的 MRI 分析

• 批准号: 6351597
• 负责人: XUE-QIAO ZHAO
• 金额: $ 22.9万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-02-01 至 2004-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6351597
• 关键词: antihyperlipoproteinemic agent; atherosclerotic plaque; bioimaging /biomedical imaging; blood lipoprotein metabolism; cardiovascular disorder chemotherapy; carotid artery; clinical research; coronary disorder; diagnosis design /evaluation; human subject; human therapy evaluation; magnetic resonance imaging

The hypothesis of lipid depletion for plaque and clinical stability has been established based on observations from animal studies, the relation between human coronary plaque features and unstable clinical episodes, and angiographic regression and clinical event reduction with lipid-lowering therapy. However, the effect of lipid-lowering therapy on human atherosclerotic plaque composition in vivo has not been possible, to date. Magnetic resonance imaging (MRI) is ideal for longitudinal studies of atherosclerotic arteries because it is noninvasive and is superior to other imaging modalities in discriminating tissue contrast. Encouraging results from our pilot study show that prolonged intensive lipid-lowering therapy appears to be associated with a decreased lipid composition in the plaque, which is considered to predict greater plaque stability. We propose to perform carotid MRI studies in 60 CAD patients with a family history of cardiovascular disease and ApoB equal to or greater than 125 mg/dl. These patients will be randomized to triple lipid-lowering therapy (atorvastatin 10-40 mg/day, niacin 2-3 gm/day, and colestipol 20 gm/day) or to mono-statin therapy (atorvastatin 20-80 mg/day), and will undergo MRI examination of both carotid arteries annually for three years, a total of 4 examinations. We will: 1) test the hypothesis that intensive lipid-lowering therapy depletes plaque lipid composition identified by MRI in carotid arteries in CAD patients and examine the relationship between depletion of plaque lipid and other plaque components and plaque regression; 2) determine the time- course of atherosclerotic plaque lipid depletion during lipid- lowering by assessing serial carotid MRI examinations; 3) continue the development of this noninvasive approach to characterize human carotid atherosclerotic plaque composition in vivo by MRI. This study employs a state-of-the art technique to assess both the magnitude and mechanisms of benefit of lipid- lowering. It will be one of the first studies to examine the effects of lipid-lowering therapy on human atherosclerotic plaques in vivo and will provide novel insights into our understanding of atherosclerotic plaque pathology and the mechanisms of lipid-lowering therapy preventing ischemic events.

基于动物实验的观察，人类冠状动脉斑块特征与不稳定临床发作的关系，以及降脂治疗后血管造影消退和临床事件减少，建立了斑块脂质消耗和临床稳定假说。然而，到目前为止，降脂治疗对体内人类动脉粥样硬化斑块组成的影响尚不可能。磁共振成像（MRI）是动脉粥样硬化动脉纵向研究的理想选择，因为它是非侵入性的，在区分组织对比方面优于其他成像方式。我们的初步研究令人鼓舞的结果表明，长期强化降脂治疗似乎与斑块中脂质成分的减少有关，这被认为预示着斑块的稳定性。我们建议对60例有心血管疾病家族史且ApoB等于或大于125 mg/dl的CAD患者进行颈动脉MRI研究。这些患者将随机接受三线降脂治疗（阿托伐他汀10- 40mg /天，烟酸2- 3gm /天，胆固醇20 gm/天）或单他汀治疗（阿托伐他汀20- 80mg /天），并将接受MRI检查双颈动脉，为期三年，共4次检查。我们将：1)验证强化降脂治疗会消耗CAD患者颈动脉MRI识别的斑块脂质成分的假设，并研究斑块脂质和其他斑块成分的消耗与斑块消退之间的关系；2)通过评估颈动脉MRI连续检查来确定降脂过程中动脉粥样硬化斑块脂质消耗的时间过程；3)继续发展这种无创的方法，通过MRI来表征人颈动脉粥样硬化斑块的组成。本研究采用最先进的技术来评估降脂益处的大小和机制。这将是第一个在体内检测降脂治疗对人类动脉粥样硬化斑块影响的研究之一，并将为我们对动脉粥样硬化斑块病理和降脂治疗预防缺血性事件的机制的理解提供新的见解。